OTIC Otonomy, Inc. Stock Quote

OTIC [NASD]

Index	-	P/E	-	EPS (ttm)	-1.03	Insider Own	0.90%	Shs Outstand	52.32M	Perf Week	-0.42%
Market Cap	134.75M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	-81.66%	Shs Float	36.74M	Perf Month	11.90%
Income	-45.20M	PEG	-	EPS next Q	-0.17	Inst Own	58.00%	Short Float	2.87%	Perf Quarter	-15.16%
Sales	0.20M	P/S	673.74	EPS this Y	24.70%	Inst Trans	-6.25%	Short Ratio	2.17	Perf Half Y	-54.46%
Book/sh	1.07	P/B	2.20	EPS next Y	28.90%	ROA	-48.00%	Target Price	-	Perf Year	-18.97%
Cash/sh	1.29	P/C	1.83	EPS next 5Y	20.40%	ROE	-83.00%	52W Range	2.01 - 6.98	Perf YTD	-63.68%
Dividend	-	P/FCF	-	EPS past 5Y	15.70%	ROI	-53.40%	52W High	-66.35%	Beta	1.98
Dividend %	-	Quick Ratio	7.10	Sales past 5Y	-	Gross Margin	-	52W Low	16.92%	ATR	0.14
Employees	56	Current Ratio	7.20	Sales Q/Q	-50.00%	Oper. Margin	-	RSI (14)	50.37	Volatility	5.58% 6.30%
Optionable	Yes	Debt/Eq	0.27	EPS Q/Q	38.90%	Profit Margin	-	Rel Volume	0.35	Prev Close	2.33
Shortable	Yes	LT Debt/Eq	0.24	Earnings	May 11 AMC	Payout	-	Avg Volume	486.15K	Price	2.35
Recom	1.80	SMA20	0.13%	SMA50	1.46%	SMA200	-37.34%	Volume	173,259	Change	0.86%

Jun-01-20

Resumed

Oppenheimer

Outperform

Dec-24-19

Initiated

Oppenheimer

Outperform

Mar-19-18

Downgrade

JP Morgan

Neutral → Underweight

Mar-12-18

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-30-17

Downgrade

Piper Jaffray

Overweight → Neutral

Aug-30-17

Downgrade

JP Morgan

Overweight → Neutral

Aug-15-17

Upgrade

JP Morgan

Neutral → Overweight

Jun-02-17

Initiated

Piper Jaffray

Overweight

$32

May-26-16

Initiated

WallachBeth

Buy

$29

Aug-10-15

Upgrade

Bernstein

Mkt Perform → Outperform

May-22-15

Downgrade

JP Morgan

Overweight → Neutral

May-14-21 02:59PM	Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows Benzinga
07:30AM	Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting GlobeNewswire
May-11-21 04:17PM	Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Otonomy, Inc. to Host Earnings Call ACCESSWIRE
May-04-21 07:30AM	Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update GlobeNewswire -5.00%
Apr-28-21 07:30AM	Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting GlobeNewswire +5.11%
Apr-19-21 07:30AM	Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +5.43%
Apr-07-21 10:02PM	Otonomy Announces Pricing of $30.1 Million Public Offering GlobeNewswire
04:06PM	Otonomy Announces Proposed Public Offering GlobeNewswire
Apr-06-21 07:30AM	Otonomy to Present at the Needham Virtual Healthcare Conference GlobeNewswire
Apr-05-21 07:30AM	Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting GlobeNewswire
Mar-25-21 07:30AM	Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus GlobeNewswire
Feb-26-21 11:01AM	Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock? Zacks
Feb-25-21 07:30AM	Otonomy to Participate in Three Upcoming Investor Conferences GlobeNewswire
Feb-22-21 09:32AM	ROCE Insights For Otonomy Benzinga -44.34%
08:37AM	Otonomy stock loses half its value after disappointing trial results of vertigo treatment MarketWatch
07:23AM	Otonomy's OTIVIDEX Fails To Separate From Placebo In Inner Ear Disorder Study Benzinga
07:00AM	Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease GlobeNewswire
Feb-17-21 07:30AM	Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting GlobeNewswire +8.48%
Feb-12-21 01:31AM	Otonomy (OTIC) Q4 2020 Earnings Call Transcript Motley Fool
Feb-11-21 04:17PM	Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Otonomy, Inc. to Host Earnings Call ACCESSWIRE
Feb-04-21 07:30AM	Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update GlobeNewswire +14.26%
04:22AM	Is Otonomy (NASDAQ:OTIC) Weighed On By Its Debt Load? Simply Wall St.
Jan-05-21 07:30AM	Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire
Dec-17-20 07:00AM	Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss GlobeNewswire +7.36%
Dec-15-20 07:50PM	Is OTIC A Good Stock To Buy Now? Insider Monkey +5.77%
Dec-14-20 08:59AM	Otonomy (OTIC) Looks Good: Stock Adds 5% in Session Zacks
Nov-30-20 07:30AM	Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs GlobeNewswire
Nov-16-20 07:30AM	Otonomy to Participate in Two Upcoming Investor Conferences GlobeNewswire
Nov-06-20 09:03AM	Otonomy, Inc. (NASDAQ:OTIC) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates Simply Wall St.
Nov-04-20 06:55PM	Otonomy (OTIC) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:03PM	Otonomy: Q3 Earnings Insights Benzinga
04:17PM	Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Otonomy, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 07:30AM	Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
Oct-02-20 07:30AM	Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménières Disease GlobeNewswire +6.22%
Sep-15-20 08:52AM	What Kind Of Shareholders Hold The Majority In Otonomy, Inc.'s (NASDAQ:OTIC) Shares? Simply Wall St.
Sep-10-20 08:41AM	Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock? Zacks
Sep-02-20 07:30AM	Otonomy to Participate in Four Upcoming Investor Conferences GlobeNewswire
Aug-17-20 03:30PM	Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks TipRanks +11.31%
Aug-04-20 07:25PM	Otonomy (OTIC) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:22PM	Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-20 07:30AM	Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program GlobeNewswire
Jul-28-20 04:05PM	Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update GlobeNewswire
Jul-15-20 01:15PM	Steven Cohen Homes in on Otonomy GuruFocus.com +6.62%
Jul-13-20 04:01PM	Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -7.38%
09:08AM	Otonomy (OTIC) Catches Eye: Stock Jumps 9.1% Zacks
Jul-09-20 09:00AM	Otonomy Announces Pricing of $60.1 Million Public Offering GlobeNewswire +8.15%
Jul-08-20 09:01PM	Otonomy Announces Proposed Public Offering GlobeNewswire
Jul-07-20 10:44AM	Why Otonomy's Stock Is Trading Higher Today Benzinga +11.95%
05:51AM	Otonomy Pops 15% in Pre-Market Fueled By Otividex Data, Positive Results From Tinnitus Candidate SmarterAnalyst
Jul-06-20 04:04PM	Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus GlobeNewswire
04:02PM	Otonomy Provides Update on OTIVIDEX® Program GlobeNewswire
Jun-30-20 11:42PM	Were Hedge Funds Right About Piling Into Otonomy Inc (OTIC)? Insider Monkey -5.73%
Jun-17-20 08:31AM	Analysts Are Betting On Otonomy, Inc. (NASDAQ:OTIC) With A Big Upgrade This Week Simply Wall St.
Jun-15-20 04:05PM	Otonomy Provides Update on Clinical Trials and Development Programs GlobeNewswire
Jun-11-20 08:41AM	Otonomy (OTIC) in Focus: Stock Moves 6.1% Higher Zacks -9.09%
07:30AM	Otonomy to Present at Raymond James 2020 Human Health Innovation Conference GlobeNewswire
Jun-10-20 07:30AM	Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020 GlobeNewswire +6.11%
Jun-08-20 07:30AM	Otonomy to Host Pipeline Program Update Conference Call and Webcast GlobeNewswire +6.44%
Jun-01-20 09:56AM	3 Strong Buy Biotech Stocks Under $5 With Major Catalysts Approaching TipRanks
May-28-20 08:32AM	Health Check: How Prudently Does Otonomy (NASDAQ:OTIC) Use Debt? Simply Wall St.
May-12-20 08:00AM	Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program GlobeNewswire
May-07-20 07:30AM	Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Apr-09-20 07:30AM	Otonomy Provides Business Update Related to COVID-19 Pandemic GlobeNewswire
Mar-26-20 06:47PM	Edited Transcript of OTIC earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-09-20 03:53PM	Easy Come, Easy Go: How Otonomy (NASDAQ:OTIC) Shareholders Got Unlucky And Saw 91% Of Their Cash Evaporate Simply Wall St. -7.84%
Feb-27-20 07:25PM	Otonomy (OTIC) Reports Q4 Loss, Misses Revenue Estimates Zacks -6.17%
04:15PM	Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Feb-24-20 07:30AM	Otonomy to Present at Two Upcoming Investor Conferences GlobeNewswire
Feb-21-20 08:37AM	Do Options Traders Know Something About Otonomy (OTIC) Stock We Don't? Zacks
Feb-20-20 07:30AM	Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update GlobeNewswire
Jan-28-20 07:30AM	Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program GlobeNewswire
Jan-23-20 07:30AM	Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting GlobeNewswire
Jan-09-20 07:30AM	Otonomy Provides Corporate and Product Pipeline Update GlobeNewswire
Jan-07-20 12:31PM	Should You Worry About Otonomy, Inc.'s (NASDAQ:OTIC) CEO Salary Level? Simply Wall St.
Jan-02-20 07:28AM	Will Otonomy Continue to Surge Higher? Zacks
Dec-24-19 07:24AM	The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga +9.52%
Dec-16-19 05:45AM	Otonomy Inc (OTIC): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-03-19 08:51AM	Top Ranked Momentum Stocks to Buy for December 3rd Zacks
Nov-26-19 04:05PM	Otonomy to Participate in Two Upcoming Investor Conferences GlobeNewswire
Nov-22-19 07:11AM	Edited Transcript of OTIC earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 06:55PM	Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:13PM	Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Oct-29-19 04:05PM	Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
11:23AM	What Kind Of Investor Owns Most Of Otonomy, Inc. (NASDAQ:OTIC)? Simply Wall St.
Oct-28-19 10:32AM	Analysts Estimate Otonomy (OTIC) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-01-19 07:30AM	AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss GlobeNewswire -6.28%
Sep-26-19 04:05PM	Otonomy to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-17-19 07:30AM	Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss GlobeNewswire
Aug-27-19 07:10AM	Edited Transcript of OTIC earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-01-19 04:20PM	Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire -6.34%
Jul-25-19 04:05PM	Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update GlobeNewswire
Jul-11-19 12:33PM	Why Otonomy, Inc. (NASDAQ:OTIC) Is An Attractive Investment To Consider Simply Wall St.
Jun-12-19 08:00AM	Otonomy to Present at the Raymond James Life Sciences and MedTech Conference GlobeNewswire +5.96%
May-14-19 05:47AM	Edited Transcript of OTIC earnings conference call or presentation 6-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-06-19 06:35PM	Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:31PM	Otonomy: 1Q Earnings Snapshot Associated Press
04:17PM	Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Meniere's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lichter Jay	Director	Mar 03	Sale	2.70	321,180	866,544	0	Mar 03 08:06 PM
Lichter Jay	Director	Mar 02	Sale	2.90	389,574	1,129,375	113,935	Mar 02 07:51 PM
Lichter Jay	Director	Mar 01	Sale	2.86	173,700	496,087	252,134	Mar 02 07:51 PM
Lichter Jay	Director	Feb 26	Sale	2.83	330,554	935,468	313,753	Mar 02 07:51 PM
Lichter Jay	Director	Feb 25	Sale	2.95	311,100	918,989	431,015	Feb 25 09:56 PM
Lichter Jay	Director	Feb 24	Sale	2.98	503,135	1,500,349	541,376	Feb 25 09:56 PM
Lichter Jay	Director	Feb 23	Sale	2.89	268,118	774,325	719,860	Feb 25 09:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience